

Whey proteins isolate supplementation in additional to nutritional counseling in cancer patients

JACOPO GIULIANI¹, FEDERICA VIGNALE², BEATRICE MANTOAN³, ANDREA BONETTI¹

¹Department of Oncology; ²Diet Service; ³Department of Diagnostic Imaging Az. ULSS 9 Scaligera, Legnago (VR), Italy.

Received on February 7, 2022. Accepted on March 18, 2022.

Dear Editor,

it is now well recognized that malnutrition is a hot topic in the management of the cancer patients and it is related to an impairment quality of life and a worse overall prognosis, due to prolonged hospitalization, higher degree of treatment-related toxicity and reduced response to cancer treatment¹. Whey proteins isolate (WPI) supplementation in addition to nutritional counseling (NC) in malnourished advanced cancer patients (82 patients versus (vs.) 84 patients without WPI supplementation (only NC)) undergoing chemotherapy resulted in improved body composition, muscle strength, body weight, and reduced chemotherapy toxicity in a randomized controlled trial (RCT)².

The aim of this paper was to evaluate the change in body weight (BW) since the introduction on WPI supplementation in addition to NC in cancer patients in real-life. The rationale is the evidence of how the intake of WPI is particularly useful in the treatment of subjects with sarcopenia due to malnutrition, aging or chronic diseases. The choice to consider the change in BW as the primary endpoint of the study is related to both the convenience of detection in oncological daily clinical practice that its role as secondary endpoint in the only RCT².

A retrospective analysis of all consecutives patients with cancer followed at the Medical Oncology Unit of our Hospital between March 2021 and August 2021 and treated with WPI supplementation in addition to NC was performed. Chi-square-test, t-test, or Fisher's exact test was used in order to identify any possible relationship between results and the different prognostic variables.

We evaluated 19 patients. Median age was 71 years old (range: 51-82). At the last follow-up 7 patients (36.8%) were deceased and 12 patients (63.2%) were alive. The general case study is summarized in table 1. Median BW was 62 kg (range: 43-85) at baseline, 62 kg (19 patients (100.0%), range: 44-85) at the first-evaluation (median time: 29 days) and 69 kg (9 patients (47.4%), range: 44-85) at the second-evaluation (median time: 47 days). Thirteen (68.4%) patients maintained BW stability at the first-evaluation and 6 (66.7%) patients at the second-evaluation. At the chi-square-test there was no statistical relationship between the site of cancer (colorectal vs. gastrointestinal

non-colorectal vs. others) and BW stability both at the first-evaluation ($p=0.493$) that at the second-evaluation ($p=0.301$).

We are aware of the limitations of a retrospective study, the small size of the cohorts and the fact that data coming from a single Institution could reflect only the habits of that particular set of physicians; on the contrary, studies like the above, though the analysis of not selected case study, are really real life experience. In facts, the patients described here represent a complete series who underwent treatment at our Unit in the considered time frame, were treated in a homogeneous way and carefully staged before the beginning of treatment and at regular intervals thereafter.

Table 1. The general case study.

| Variable | Value | Number of patients (%) |
|------------------------------|-----------------|------------------------|
| Age | <65 years | 5 (26.3) |
| | ≥65 years | 14 (73.7) |
| Sex | female | 6 (31.6) |
| | male | 13 (68.4) |
| Site | stomach | 6 (31.6) |
| | lung | 4 (21.1) |
| | colorectal | 4 (21.1) |
| | pancreas | 3 (15.8) |
| | oesophagus | 1 (5.3) |
| | breast | 1 (5.3) |
| Stage | early | 3 (15.8) |
| | advanced | 16 (84.2) |
| Active oncological treatment | yes | 15 (78.9) |
| | no | 4 (21.1) |
| Type of treatment | chemotherapy | 9 (60.1) |
| | immune-therapy | 2 (13.3) |
| | targeted agents | 2 (13.3) |
| | hormone-therapy | 2 (13.3) |

On our knowledge, this is the first experience of WPI supplementation in addition to NC in cancer patients in daily clinical practice.

In conclusion, we found that the additional provision of WPI to malnourished cancer patients receiving NC maintained BW in most patients (regardless of the site) and in a relatively short time. Patients who continue to provision WPI in addition to NC for more than a month seems to improve BW.

Authorship: all authors contributed equally to (1) conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published.

Conflict of interests: the authors have no relevant affiliations or financial involvement with any organization or entity with a financial

interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

1. Caccialanza R, Pedrazzoli P, Cereda E, et al. Nutritional support in cancer patients: a Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). *J Cancer* 2016; 7: 131-5.
2. Cereda E, Turri A, Klersy C, et al. Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. *Cancer Med* 2019; 8: 6923-32.



Una diversa fiducia

Per un nuovo rapporto nelle relazioni di cura

A cura di **Sandro Spinsanti**

232 pagine. € 19,00

Il Pensiero Scientifico Editore
www.pensiero.it